Interagency Patent Coordination and Improvement Act of 2025 was reported by committee and awaits a floor vote
Written by the Congressional Research Service [2]. 152 words.
Interagency Patent Coordination and Improvement Act of 2025 This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
- Committees
- Senate Judiciary Committee
- Policy area
- Commerce: 44 of 2,416 bills became law, 113th–118th (1.8%)
- Sponsor
- 6 of 577 bills enacted since 2013
- Text versions
- 2, from introduced in senate to reported to senate · 1,446 words
- Subjects
- Drug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Intellectual propertyIntergovernmental relations
- Latest action
- Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 1 in all.
Related, per CRS or House · 1
- 119th H.R. 4570 Interagency Patent Coordination and Improvement Act of 2025 D · Introduced